You will get better answers from others, however my understanding is that the FDA requested (demanded) that they be studied in aggregate for the BoM primary endpoint. my understanding is that they were also studied independently in BoM sub-studies.

We are waiting on pins & needles for the release of FLD in November at the AHA conference, and the results of the sub-studies, as well as secondary endpoints.